Spyre Therapeutics $300M Stock Offering

Spyre Therapeutics announced a $300 million underwritten public offering of common stock, with a 30‑day option for an extra $45 million.
Shares fell about 2% in after‑hours trading on April 14, 2026, after the offering announcement, despite a 23.26% intraday surge earlier.
Underwriters include Jefferies, Goldman Sachs, Evercore ISI, Guggenheim Securities, with LifeSci Capital as passive bookrunner.
The biotech focuses on IBD treatments, with pipeline antibodies targeting a4p7, TL1A, and IL‑23.